https://crinetics.com/press-releases/ 2026-02-05T21:12:22+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-awarded-national-institutes-of-health-small-business-innovative-research-grant-to-develop-gpcr-biosensors-for-drug-discovery/ 2009-02-07T12:31:02+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-awarded-nih-phase-ii-sbir-grant-to-develop-drugs-for-pituitary-tumors/ 2013-09-13T19:36:00+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-awarded-nih-phase-i-sbir-grant-to-develop-somatostatin-receptor-agonist-drugs-for-ophthalmic-diseases/ 2014-04-28T16:38:09+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-awarded-1-5mm-nih-phase-ii-sbir-grant-to-develop-kisspeptin-receptor-antagonists-for-pcos-and-other-womens-health-diseases/ 2015-01-28T17:38:10+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-awarded-nih-fast-track-grant-to-develop-somatostatin-receptor-agonist-drugs-for-chronic-pain/ 2015-04-27T16:38:10+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-appoints-matt-fust-m-b-a-david-clemons-m-d-and-john-wallen-ph-d-j-d-as-corporate-clinical-and-legal-advisers/ 2015-04-27T16:38:11+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-completes-40-million-series-a-financing/ 2015-11-02T17:38:11+00:00 https://crinetics.com/press-releases/the-san-diego-union-tribune-crinetics-raises-40-million/ 2015-11-02T12:51:22+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-appoints-ajay-madan-as-vice-president-development/ 2016-06-06T16:38:12+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-appoints-anne-klibanski-m-d-to-scientific-advisory-board/ 2016-11-10T17:43:24+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-awarded-2-8-million-sbir-grant-to-support-development-of-acromegaly-drug-candidate-crn00808/ 2017-07-13T16:43:25+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-awarded-two-sbir-grants-to-develop-new-therapeutics-for-congenital-hyperinsulinism-and-cushings-disease/ 2017-09-06T16:43:25+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-initiates-phase-1-study-of-lead-candidate-crn00808-for-acromegaly/ 2017-10-26T16:43:26+00:00 https://crinetics.com/press-releases/crinetics-ceo-talks-with-pituitary-world-news-about-the-importance-of-patient-advocacy-in-developing-new-medicines/ 2017-11-14T12:52:41+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference/ 2018-01-02T17:43:26+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-appoints-marc-wilson-as-chief-financial-officer/ 2018-01-04T17:43:26+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-present-at-cowen-and-company-38th-annual-health-care-conference/ 2018-03-07T17:43:27+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-upcoming-presentations-at-endo-2018/ 2018-03-12T16:43:27+00:00 https://crinetics.com/press-releases/crinetics-completes-635-million-series-b-financing/ 2018-03-13T16:43:29+00:00 https://crinetics.com/press-releases/top-news-crinetics-raises-63-5-million-in-new-funds-and-adds-to-bod/ 2018-03-13T19:57:14+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-appoints-alan-krasner-m-d-as-chief-medical-officer/ 2018-06-18T16:43:28+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-awarded-up-to-3-2-million-in-sbir-grants-for-congenital-hyperinsulinism-and-acromegaly/ 2018-06-21T14:30:11+00:00 https://crinetics.com/press-releases/crinetics-announces-pricing-initial-public-offering/ 2018-07-17T11:44:31+00:00 https://crinetics.com/press-releases/crinetics-closes-initial-public-offering/ 2018-07-20T11:44:52+00:00 https://crinetics.com/press-releases/2018-corporate-update-second-quarter-financial-results/ 2018-08-30T11:44:45+00:00 https://crinetics.com/press-releases/2018-leerink-partners-rare-disease-oncology/ 2018-09-26T12:55:53+00:00 https://crinetics.com/press-releases/2018-3rd-quarter-financial-results-corporate-update/ 2018-11-03T11:44:23+00:00 https://crinetics.com/press-releases/crinetics-2019-jp-morgan-healthcare-conference/ 2019-01-02T12:44:01+00:00 https://crinetics.com/press-releases/2019-svb-leerink-global-healthcare-conference/ 2019-02-21T12:44:55+00:00 https://crinetics.com/press-releases/2018-final-quarter-financial-corporate-update/ 2019-03-13T11:44:44+00:00 https://crinetics.com/press-releases/crinetics-announces-upcoming-presentations-endo2019/ 2019-03-14T11:44:26+00:00 https://crinetics.com/press-releases/gina-ford-named-vp-corporate-strategy/ 2019-03-18T11:44:44+00:00 https://crinetics.com/press-releases/patients-dosed-in-phase-2-clinical-trials-acromegaly/ 2019-03-19T11:44:53+00:00 https://crinetics.com/press-releases/crinetics-1st-quarter-2019-finance-corporate-update/ 2019-05-13T11:44:21+00:00 https://crinetics.com/press-releases/phase1-study-treatment-neuroendocrine-tumors/ 2019-05-21T11:44:11+00:00 https://crinetics.com/press-releases/stephanie-okey-appointed-to-board-of-directors/ 2019-07-16T11:44:51+00:00 https://crinetics.com/press-releases/crinetics-final-nih-grant-congenital-hyperinsulinism/ 2019-07-29T11:44:18+00:00 https://crinetics.com/press-releases/2019-second-quarter-financial-results-and-corporate-update/ 2019-08-13T12:55:04+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-present-at-h-c-wainwright-global-investment-conference/ 2019-09-03T05:55:36+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-cantor-global-healthcare-conference/ 2019-09-25T06:07:47+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-third-quarter-2019-financial-results-and-provides-corporate-update/ 2019-11-12T06:06:58+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-the-piper-jaffray-healthcare-conference/ 2019-11-26T07:58:29+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-present-at-j-p-morgan-healthcare-conference-2/ 2020-01-08T08:08:59+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-svb-leerink-global-healthcare-conference/ 2020-02-19T08:09:00+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-and-provides-corporate-update/ 2020-03-09T08:09:02+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-positive-interim-results-for-the-acrobat-edge-phase-2-trial-of-paltusotine-crn00808-in-acromegaly-patients-and-provides-corporate-update/ 2020-04-06T08:12:50+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-proposed-public-offering-of-common-stock/ 2020-04-14T05:55:11+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-proposed-public-offering-of-common-stock-2/ 2020-04-14T08:12:52+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock/ 2020-04-15T05:55:52+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares/ 2020-04-17T05:55:17+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-including-full-exercise-of-underwriters-option-to-purchase-additional-shares-2/ 2020-04-17T08:25:14+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-first-quarter-2020-financial-results-and-provides-corporate-update/ 2020-05-08T08:25:12+00:00 https://crinetics.com/press-releases/crinetics-crnx-appointments-adriana-cabre-mba-vp-of-hr/ 2020-05-27T05:55:58+00:00 https://crinetics.com/press-releases/crinetics-confirms-completion-half-enrolled-patients-ongoing-phase-2-acrobat-edge-clinical-trial-paltusotine-acromegaly/ 2020-06-11T04:30:00+00:00 https://crinetics.com/press-releases/fda-grants-crinetics-pharmaceuticals-crnx-orphan-drug-designation-paltusotine-for-the-treatment-of-acromegaly/ 2020-07-08T04:05:53+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-second-quarter-2020-financial-results-and-provides-corporate-update/ 2020-08-07T07:30:25+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-september-investor-conferences/ 2020-09-03T04:30:34+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-appoints-rare-disease-executive-camille-l-bedrosian-m-d-to-board-of-directors/ 2020-09-03T05:55:04+00:00 https://crinetics.com/press-releases/new-data-paltusotine-acth-antagonist-development-programs/ 2020-09-04T12:55:16+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-receives-rare-pediatric-disease-designation-from-fda-for-crn04777-for-the-treatment-of-congenital-hyperinsulinism/ 2020-09-21T07:30:13+00:00 https://crinetics.com/press-releases/acrobat-edge-study-of-paltusotine-in-acromegaly-met-endpoint/ 2020-10-26T11:05:08+00:00 https://crinetics.com/press-releases/third-quarter-2020-financial-results-and-corporate-update/ 2020-11-06T13:30:44+00:00 https://crinetics.com/press-releases/key-opinion-leaders-on-oral-paltusotine-acromegaly/ 2020-11-13T12:30:19+00:00 https://crinetics.com/press-releases/acromegaly-expert-peter-trainer-vp-clinical-endocrinology/ 2020-11-16T12:31:10+00:00 https://crinetics.com/press-releases/crinetics-december-investor-conferences/ 2020-11-23T12:30:14+00:00 https://crinetics.com/press-releases/crinetics-announces-2021-plans-jp-morgan-conference/ 2021-01-06T12:05:45+00:00 https://crinetics.com/press-releases/crn04777-congenital-hyperinsulinism-phase1-study/ 2021-02-03T12:10:25+00:00 https://crinetics.com/press-releases/lead-acth-antagonist-crn04894-enters-phase1-study/ 2021-02-04T12:10:09+00:00 https://crinetics.com/press-releases/endo-2021-presentations-showcase-three-clinical-programs/ 2021-03-12T12:10:46+00:00 https://crinetics.com/press-releases/pipeline-progress-endo-2021/ 2021-03-22T11:10:34+00:00 https://crinetics.com/press-releases/webcast-clinical-plans-fourth-quarter-2020-financial-results/ 2021-03-24T11:10:21+00:00 https://crinetics.com/press-releases/2021-clinical-plans-4th-quarter-2020-financial-results/ 2021-03-30T20:05:16+00:00 https://crinetics.com/press-releases/crinetics-announces-pricing-of-common-stock-offering/ 2021-04-07T22:34:51+00:00 https://crinetics.com/press-releases/crinetics-announces-closing-of-common-stock-offering/ 2021-04-12T20:05:16+00:00 https://crinetics.com/press-releases/quarter-1-2021-financial-results-corporate-update/ 2021-05-06T20:45:23+00:00 https://crinetics.com/press-releases/crinetics-appoints-garlan-adams-as-general-counsel/ 2021-06-16T12:30:07+00:00 https://crinetics.com/press-releases/first-patient-pathfndr1-paltusotine-phase-3-study/ 2021-06-28T11:30:28+00:00 https://crinetics.com/press-releases/15-million-frazier-healthcare-partners/ 2021-07-29T11:31:29+00:00 https://crinetics.com/press-releases/crn04894-demonstrates-pharmacologic-proof-of-concept/ 2021-08-10T20:01:19+00:00 https://crinetics.com/press-releases/crinetics-second-quarter-2021-financial-results-corporate-update/ 2021-08-10T20:01:54+00:00 https://crinetics.com/press-releases/crinetics-appoints-jeff-knight-as-chief-operating-officer/ 2021-09-02T11:30:24+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-september-investor-conferences/ 2021-09-07T11:30:13+00:00 https://crinetics.com/press-releases/crn04777-demonstrates-dose-dependent-supression-of-insulin-secretion-phase1-sad-study/ 2021-09-15T20:01:40+00:00 https://crinetics.com/press-releases/crinetics-unveils-parathyroid-hormone-receptor-antagonist-program-at-asbmr/ 2021-09-27T11:30:12+00:00 https://crinetics.com/press-releases/radionetics-radiopharmaceuticals-crnx-pipeline/ 2021-10-18T20:00:32+00:00 https://crinetics.com/press-releases/crinetics-announces-proposed-public-offering-102021/ 2021-10-20T20:01:37+00:00 https://crinetics.com/press-releases/crinetics-prices-public-offering-102121/ 2021-10-21T13:16:55+00:00 https://crinetics.com/press-releases/crinetics-closes-common-stock-public-offering-102521/ 2021-10-25T20:01:28+00:00 https://crinetics.com/press-releases/crinetics-crnx-q3-2021-financial-update/ 2021-11-05T12:00:11+00:00 https://crinetics.com/press-releases/crinetics-presents-acromegal-ole-results-110821/ 2021-11-08T16:09:29+00:00 https://crinetics.com/press-releases/crinetics-presents-at-evercore-isi-healthconx-111821/ 2021-11-18T13:00:15+00:00 https://crinetics.com/press-releases/rare-disease-expert-vivaldi-joins-crinetics-board/ 2022-01-05T12:40:18+00:00 https://crinetics.com/press-releases/presents-at-annual-jpmorgan-healthcare-conference-2022/ 2022-01-12T12:40:19+00:00 https://crinetics.com/press-releases/crinetics-inducement-grants-020122/ 2022-02-01T21:45:43+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-present-at-svb-leerink-healthcare-conference/ 2022-02-09T12:30:33+00:00 https://crinetics.com/press-releases/crinetics-skk-partner-paltusotine-deveopment-japan/ 2022-02-28T11:00:54+00:00 https://crinetics.com/press-releases/crinetics-appoints-james-hassard-chief-commercial-officer/ 2022-03-01T11:00:51+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-inducement-grants-2022-0310/ 2022-03-10T22:00:09+00:00 https://crinetics.com/press-releases/crinetics-appoints-caren-deardorf-boardofdirectors/ 2022-03-14T10:01:57+00:00 https://crinetics.com/press-releases/crinetics-chief-business-officer-chris-robillard/ 2022-03-21T11:30:08+00:00 https://crinetics.com/press-releases/crinetics-reports-fourth-quarter-year-end-2021-financial-results/ 2022-03-30T20:00:18+00:00 https://crinetics.com/press-releases/crinetics-positive-topline-crn04777-phase-1-mad-study/ 2022-03-30T20:01:50+00:00 https://crinetics.com/press-releases/april-2022-inducement-grants/ 2022-04-12T00:15:16+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-pricing-of-underwritten-common-stock-offering-april-2022/ 2022-04-13T17:55:16+00:00 https://crinetics.com/press-releases/crinetics-closes-underwritten-public-offering-04182022/ 2022-04-18T20:01:14+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2022-05-10T20:43:08+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-first-quarter-2022-financial-results-and-provides-corporate-update/ 2022-05-12T20:42:36+00:00 https://crinetics.com/press-releases/crinetics-reports-topline-crn04894-phase-1-mad-results/ 2022-05-25T11:01:03+00:00 https://crinetics.com/press-releases/crinetics-to-present-at-jmp-live-sciences-2022/ 2022-06-07T11:30:26+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-endo2022/ 2022-06-08T11:31:59+00:00 https://crinetics.com/press-releases/june-2022-inducement-grants/ 2022-06-10T19:47:28+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-presenting-crn04894-preclinical-and-phase-1-at-icn2022/ 2022-07-12T05:02:00+00:00 https://crinetics.com/press-releases/july-2022-inducement-grants/ 2022-07-12T21:10:00+00:00 https://crinetics.com/press-releases/crinetics-announces-august-2022-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2022-08-10T08:45:33+00:00 https://crinetics.com/press-releases/crinetics-reports-second-quarter-2022-financial-results-and-provides-corporate-update/ 2022-08-12T12:02:34+00:00 https://crinetics.com/press-releases/long-term-safety-efficacy-data-paltusotine-cbem/ 2022-09-02T12:05:08+00:00 https://crinetics.com/press-releases/two-year-data-from-advance-ole-study-presented-at-cbem/ 2022-09-06T12:02:54+00:00 https://crinetics.com/press-releases/hc-wainwright-24th-annual-investment-conference/ 2022-09-08T12:01:29+00:00 https://crinetics.com/press-releases/crinetics-092022-inducement-grants-nasdaq-5635c4/ 2022-09-12T12:02:03+00:00 https://crinetics.com/press-releases/crinetics-appoints-dana-pizzuti-chief-development-officer/ 2022-10-03T12:03:56+00:00 https://crinetics.com/press-releases/innovation-passport-congenital-hyperinsulinism/ 2022-10-06T12:02:15+00:00 https://crinetics.com/press-releases/crinetics-announces-october-2022-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2022-10-10T20:58:40+00:00 https://crinetics.com/press-releases/pathfndr1-enrollment-complete-paltusotine-acromegaly/ 2022-10-13T12:02:13+00:00 https://crinetics.com/press-releases/crinetics-announces-november-2022-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2022-11-10T20:11:10+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-corporate-update/ 2022-11-14T13:04:46+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-the-5th-annual-evercore-isi-healthconx-conference/ 2022-11-22T13:02:47+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-provides-update-on-crn04777-program/ 2022-11-28T13:02:05+00:00 https://crinetics.com/press-releases/crinetics-announces-december-2022-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2022-12-12T09:02:45+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-present-corporate-and-clinical-update-at-41st-annual-j-p-morgan-healthcare-conference/ 2023-01-09T13:03:15+00:00 https://crinetics.com/press-releases/crinetics-announces-january-2023-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2023-01-10T21:48:53+00:00 https://crinetics.com/press-releases/crinetics-to-participate-in-svb-global-biopharma-conference-2023/ 2023-02-10T13:02:00+00:00 https://crinetics.com/press-releases/crinetics-announces-february-2023-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2023-02-10T22:23:25+00:00 https://crinetics.com/press-releases/crinetics-reports-fourth-quarter-and-full-year-2022-financial-results/ 2023-02-28T21:05:25+00:00 https://crinetics.com/press-releases/crinetics-announces-march-2023-inducement-grants-under-nasdaq-listing-rule-5635c4-2/ 2023-03-10T09:38:29+00:00 https://crinetics.com/press-releases/crinetics-announces-april-2023-inducement-grants-under-nasdaq-listing-rule-5635c4-2/ 2023-04-09T14:01:34+00:00 https://crinetics.com/press-releases/crinetics-reports-first-quarter-2023-financial-results-and-provides-corporate-update/ 2023-05-04T17:21:55+00:00 https://crinetics.com/press-releases/crinetics-announces-may-2023-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2023-05-10T20:23:43+00:00 https://crinetics.com/press-releases/crinetics-to-highlight-broad-pipeline-at-endo-2023/ 2023-06-09T11:32:10+00:00 https://crinetics.com/press-releases/crinetics-announces-june-2023-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2023-06-12T11:31:23+00:00 https://crinetics.com/press-releases/data-demonstrating-stable-biochemical-and-symptom-levels-with-two-years-of-oral-paltusotine-presented-at-endo-2023/ 2023-06-21T12:01:28+00:00 https://crinetics.com/press-releases/crinetics-announces-july-2023-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2023-07-10T20:20:18+00:00 https://crinetics.com/press-releases/crinetics-hosting-kol-webinar-on-acromegaly-treatment-landscape-and-unmet-need/ 2023-07-31T12:01:25+00:00 https://crinetics.com/press-releases/crinetics-reports-second-quarter-2023-financial-results-and-provides-corporate-update/ 2023-08-08T11:02:21+00:00 https://crinetics.com/press-releases/crinetics-announces-august-2023-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2023-08-11T00:36:03+00:00 https://crinetics.com/press-releases/crinetics-announces-september-2023-inducement-grants/ 2023-09-09T10:00:18+00:00 https://crinetics.com/press-releases/crinetics-paltusotine-achieved-primary-and-secondary-endpoints-in-phase-3-pathfndr-1-acromegaly-study/ 2023-09-10T14:00:56+00:00 https://crinetics.com/press-releases/crinetics-announces-proposed-public-stock-offering-sep-2023/ 2023-09-11T21:57:43+00:00 https://crinetics.com/press-releases/crinetics-pricing-of-upsized-public-offering-of-common-stock/ 2023-09-13T03:06:29+00:00 https://crinetics.com/press-releases/crinetics-to-participate-in-the-2023-cantor-global-healthcare-conference/ 2023-09-20T13:17:53+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-october-2023-inducement-grants/ 2023-10-11T01:43:06+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-third-quarter-2023-financial-results-and-provides-corporate-update/ 2023-11-07T22:07:15+00:00 https://crinetics.com/press-releases/crinetics-announces-november-2023-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2023-11-10T22:07:53+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-upcoming-investor-conferences/ 2023-11-21T17:11:16+00:00 https://crinetics.com/press-releases/crinetics-announces-december-2023-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2023-12-11T21:25:44+00:00 https://crinetics.com/press-releases/crinetics-announces-positive-initial-findings-from-ongoing-open-label-phase-2-study-of-paltusotine-for-the-treatment-of-carcinoid-syndrome/ 2023-12-18T21:05:07+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-the-42nd-annual-j-p-morgan-healthcare-conference/ 2024-01-03T14:42:19+00:00 https://crinetics.com/press-releases/crinetics-announces-january-2024-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2024-01-11T04:25:55+00:00 https://crinetics.com/press-releases/crinetics-announces-february-2024-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2024-02-13T00:08:05+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-oversubscribed-350-million-private-placement/ 2024-02-28T13:00:01+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results-and-provides-corporate-update/ 2024-02-28T21:25:49+00:00 https://crinetics.com/press-releases/crinetics-announces-march-2024-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2024-03-11T22:33:14+00:00 https://crinetics.com/press-releases/crinetics-announces-topline-results-from-phase-2-trial-of-paltusotine-for-the-treatment-of-carcinoid-syndrome/ 2024-03-12T20:05:10+00:00 https://crinetics.com/press-releases/crinetics-once-daily-oral-paltusotine-achieved-the-primary-and-all-secondary-endpoints-in-the-phase-3-pathfndr-2-study-in-acromegaly-patients/ 2024-03-19T10:00:00+00:00 https://crinetics.com/press-releases/crinetics-announces-april-2024-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2024-04-11T20:05:29+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-present-advancements-from-atumelnant-crn04894-and-paltusotine-development-programs-at-endo-2024/ 2024-05-08T20:05:39+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-business-update/ 2024-05-09T20:07:00+00:00 https://crinetics.com/press-releases/crinetics-announces-may-2024-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2024-05-11T02:03:29+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-early-release-of-endo-2024-late-breaking-abstracts/ 2024-05-22T12:00:13+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-appoints-robert-m-cuddihy-m-d-as-senior-vice-president-of-medical-affairs/ 2024-05-30T20:05:44+00:00 https://crinetics.com/press-releases/crinetics-presents-new-data-at-endo-2024-that-increases-that-increases-body-of-evidence-positioning-once-daily-oral-paltusotine-as-potential-first-choice-treatment-option-for-acromegaly/ 2024-06-03T16:00:32+00:00 https://crinetics.com/press-releases/crinetics-announces-positive-initial-findings-at-endo-2024-for-atumelnant-in-two-ongoing-open-label-studies-for-the-treatment-of-congenital-adrenal-hyperplasia-cah-and-acth-dependent-cushing/ 2024-06-03T16:01:25+00:00 https://crinetics.com/press-releases/crinetics-announces-june-2024-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2024-06-10T22:31:08+00:00 https://crinetics.com/press-releases/ey-announces-scott-struthers-ph-d-ceo-and-founder-of-crinetics-pharmaceuticals-as-an-entrepreneur-of-the-year-2024-pacific-southwest-award-winner/ 2024-06-18T20:35:47+00:00 https://crinetics.com/press-releases/crinetics-announces-july-2024-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2024-07-10T21:44:50+00:00 https://crinetics.com/press-releases/crinetics-launches-acro-truth-educational-initiative-to-raise-awareness-of-acromegaly-treatment-challenges/ 2024-08-08T12:30:14+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-second-quarter-2024-financial-results-and-provides-business-update/ 2024-08-08T20:05:32+00:00 https://crinetics.com/press-releases/https-crinetics-com-crinetics-announces-august-2024-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2024-08-12T20:05:38+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences/ 2024-08-29T20:17:21+00:00 https://crinetics.com/press-releases/crinetics-announces-september-2024-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2024-09-10T20:50:43+00:00 https://crinetics.com/press-releases/crinetics-submits-new-drug-application-for-paltusotine-for-the-treatment-of-acromegaly/ 2024-09-26T20:06:23+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-proposed-public-offering-of-common-stock-3/ 2024-10-08T20:03:40+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-pricing-of-upsized-public-offering-of-common-stock/ 2024-10-09T03:56:28+00:00 https://crinetics.com/press-releases/crinetics-announces-october-2024-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2024-10-10T20:45:20+00:00 https://crinetics.com/press-releases/crinetics-announces-november-2024-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2024-11-11T21:05:00+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides-business-update/ 2024-11-12T21:05:40+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-showcase-pipeline-advancements-with-neuroendocrine-tumor-candidates-at-the-north-american-neuroendocrine-tumor-society-nanets-annual-meeting/ 2024-11-12T21:07:38+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-three-upcoming-december-investor-conferences/ 2024-11-15T15:03:22+00:00 https://crinetics.com/press-releases/crinetics-announces-fda-acceptance-of-new-drug-application-for-paltusotine-for-adult-patients-with-acromegaly/ 2024-12-09T13:01:41+00:00 https://crinetics.com/press-releases/crinetics-announces-december-2024-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2024-12-11T02:05:16+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-appoints-isabel-kalofonos-as-chief-commercial-officer/ 2024-12-16T13:02:25+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-the-43rd-annual-j-p-morgan-healthcare-conference/ 2025-01-06T13:05:17+00:00 https://crinetics.com/press-releases/crinetics-announces-positive-topline-results-from-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia-cah/ 2025-01-10T12:01:58+00:00 https://crinetics.com/wp-content/uploads/2025/03/CNX-logo-for-webv2.jpg https://crinetics.com/press-releases/crinetics-announces-january-2025-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2025-01-10T22:45:43+00:00 https://crinetics.com/press-releases/crinetics-announces-february-2025-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2025-02-10T21:50:16+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-two-upcoming-march-investor-conferences/ 2025-02-20T21:06:07+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-appoints-tobin-schilke-as-chief-financial-officer/ 2025-02-24T13:32:04+00:00 https://crinetics.com/wp-content/uploads/2025/04/Tobin-Schilke-.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-update/ 2025-02-27T21:22:23+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-march-2025-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2025-03-10T20:43:04+00:00 https://crinetics.com/wp-content/uploads/2025/03/web-1000x1000-01-04-scaled.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-european-medicines-agency-ema-validation-of-marketing-authorization-application-maa-and-orphan-drug-designation-odd-for-paltusotine-in-acromegaly/ 2025-03-27T20:06:14+00:00 https://crinetics.com/wp-content/uploads/2025/03/CNX-logo-for-webv2.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-april-2025-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2025-04-10T21:05:26+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-first-quarter-2025-financial-results-and-provides-business-update/ 2025-05-08T20:05:43+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-may-2025-inducement-grants-under-nasdaq-listing-rule-5635c4-2/ 2025-05-12T20:07:03+00:00 https://crinetics.com/press-releases/crinetics-to-present-new-research-on-paltusotine-atumelnant-and-unmet-needs-in-acromegaly-treatment-at-the-american-association-of-clinical-endocrinology-annual-meeting-2025/ 2025-05-16T02:32:14+00:00 https://crinetics.com/wp-content/uploads/2025/05/Crinetics-Science-Emma-3-1.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-the-jefferies-global-healthcare-conference-2025-2/ 2025-05-23T12:03:30+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-june-2025-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2025-06-10T20:32:02+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-host-rd-day-on-june-26-2025/ 2025-06-16T12:05:42+00:00 https://crinetics.com/press-releases/crinetics-to-showcase-the-next-generation-of-endocrinology-innovation-at-endo-2025-with-eight-presentations-from-its-deep-pipeline-2/ 2025-06-30T20:06:07+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-july-2025-inducement-grants-under-nasdaq-listing-rule-5635c4-2/ 2025-07-10T20:36:07+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-report-second-quarter-2025-financial-results-on-august-7-2025/ 2025-07-11T16:05:09+00:00 https://crinetics.com/wp-content/uploads/2025/05/Card-Slider-Image.png https://crinetics.com/press-releases/crinetics-to-present-new-long-term-data-demonstrating-durable-control-of-once-daily-oral-palsonify-paltusotine-in-acromegaly-at-endo-2025/ 2025-07-13T21:46:59+00:00 https://crinetics.com/wp-content/uploads/2025/05/Card-Slider-Image-300x216.png https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business-update/ 2025-08-07T20:06:41+00:00 https://crinetics.com/wp-content/uploads/2025/05/Crinetics-Culture-Meeting-300x200.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-august-2025-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2025-08-11T20:05:49+00:00 https://crinetics.com/wp-content/uploads/2025/05/Card-Slider-Image.png https://crinetics.com/press-releases/crinetics-receives-fda-orphan-drug-designation-for-atumelnant-in-the-treatment-of-congenital-adrenal-hyperplasia-cah/ 2025-08-21T12:46:51+00:00 https://crinetics.com/wp-content/uploads/2025/05/Crinetics-Science-Pablo-4-768x512.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-september-2025-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2025-09-10T20:47:18+00:00 https://crinetics.com/press-releases/crinetics-announces-fda-approval-of-palsonify-paltusotine-for-the-treatment-of-acromegaly-in-adults/ 2025-09-25T21:30:00+00:00 https://crinetics.com/wp-content/uploads/2025/08/Crinetics-Culture-1165-scaled.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-report-third-quarter-2025-financial-results-on-november-6-2025/ 2025-10-06T20:18:21+00:00 https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-october-2025-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2025-10-10T20:48:47+00:00 https://crinetics.com/press-releases/crinetics-to-highlight-neuroendocrine-tumor-research-progress-at-the-2025-north-american-neuroendocrine-tumor-society-annual-meeting/ 2025-10-23T12:47:44+00:00 https://crinetics.com/wp-content/uploads/2025/10/mitchell-kmetz-ztVcGTSD8xw-unsplash-scaled.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-reports-third-quarter-2025-financial-results-and-provides-business-update/ 2025-11-06T21:06:00+00:00 https://crinetics.com/wp-content/uploads/2025/11/Crinetics-Scientist_300x200_Preview.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-november-2025-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2025-11-10T21:30:40+00:00 https://crinetics.com/press-releases/crinetics-announces-first-patient-randomized-in-pivotal-phase-3-carefndr-trial-evaluating-paltusotine-in-carcinoid-syndrome/ 2025-11-20T21:08:45+00:00 https://crinetics.com/wp-content/uploads/2025/08/1730475183117-768x431-1.jpg https://crinetics.com/press-releases/crinetics-announces-first-patient-dosed-in-phase-1-2-trial-evaluating-crn09682-for-the-treatment-of-neuroendocrine-tumors-and-other-somatostatin-receptor-2-expressing-tumors/ 2025-12-03T13:28:57+00:00 https://crinetics.com/wp-content/uploads/2025/12/9682-FPI-PR.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-december-2025-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2025-12-10T21:36:43+00:00 https://crinetics.com/press-releases/crinetics-announces-first-patient-dosed-in-pivotal-adult-trial-of-atumelnant-in-congenital-adrenal-hyperplasia-cah/ 2025-12-11T21:08:43+00:00 https://crinetics.com/wp-content/uploads/2025/05/Crinetics-Science-Emma-3-1-768x512.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference/ 2025-12-18T21:08:24+00:00 https://crinetics.com/wp-content/uploads/2025/12/2026-JPM-Curtain-Raiser.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference-2/ 2025-12-19T05:05:00+00:00 https://crinetics.com/wp-content/uploads/2025/12/crinetics-logo-trademark-jpg-1-jpg-6.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-provide-palsonify-business-update-and-announce-topline-results-from-fourth-cohort-of-phase-2-trial-of-atumelnant-in-congenital-adrenal-hyperplasia/ 2026-01-04T21:07:26+00:00 https://crinetics.com/wp-content/uploads/2026/01/Crinetics-Pharmaceuticals-Corporate-Press-Release.jpg https://crinetics.com/press-releases/crinetics-announces-strong-palsonify-launch-execution-and-positive-results-for-concurrent-androstenedione-lowering-and-glucocorticoid-dose-reduction-in-phase-2-trial-of-atumelnant-for-congenital-adren/ 2026-01-05T13:07:34+00:00 https://crinetics.com/wp-content/uploads/2025/08/Crinetics-Culture-1165-scaled.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-proposed-public-offering-of-common-stock-4/ 2026-01-05T21:03:49+00:00 https://crinetics.com/wp-content/uploads/2026/01/Crinetics-Pharmaceuticals-Press-Release.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-pricing-of-public-offering-of-common-stock-2/ 2026-01-07T02:28:21+00:00 https://crinetics.com/wp-content/uploads/2026/01/Crinetics-Pharmaceuticals-Press-Release_300x200.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-announces-january-2026-inducement-grants-under-nasdaq-listing-rule-5635c4/ 2026-01-12T21:46:52+00:00 https://crinetics.com/wp-content/uploads/2026/01/crinetics-logo-trademark-jpg-1-jpg-4.jpg https://crinetics.com/press-releases/crinetics-initiates-phase-2-3-pediatric-trial-evaluating-atumelnant-in-congenital-adrenal-hyperplasia-cah/ 2026-01-22T21:10:47+00:00 https://crinetics.com/wp-content/uploads/2026/01/Crinetics-Pharmaceuticals-Press-Release.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-report-fourth-quarter-and-full-year-2025-financial-results-on-february-26-2026/ 2026-01-26T22:02:04+00:00 https://crinetics.com/wp-content/uploads/2026/01/Crinetics-Pharmaceuticals-Press-Release_300x200.jpg https://crinetics.com/press-releases/crinetics-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-in-march/ 2026-02-05T21:12:22+00:00 https://crinetics.com/wp-content/uploads/2026/01/Crinetics-Pharmaceuticals-Press-Release.jpg